GlassScriptPhysician profile
Matthew J Mcmillin
NPI 1528021987
$4,535.60
in general payments reported to CMS, 2019-2025
37 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $702 · 2021: $931 · 2022: $476 · 2023: $185 · 2024: $765 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $908.72 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $442.80 | 2019-2025 | |
| Almatica Pharma LLC | $290.91 | 2021-2025 | Loreev Xr, Gralise |
| Pfizer INC. | $290.20 | 2019-2025 | |
| Lilly USA, LLC | $272.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $229.55 | 2020-2021 | |
| Novo Nordisk INC | $225.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $202.05 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $153.02 | 2019-2025 | Repatha, Evenity, Prolia |
| Allergan, INC. | $142.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $132.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.14 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.77 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.57 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $88.04 | 2019-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcmillin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.